Table 1.
Demographic data and results of screening procedures for the 24 subjects who completed the study.*
Maximum tolerated dose (mg day−1) | |||||
---|---|---|---|---|---|
Subject | Age (years) | Gender | FEV1 (% predicted) | Diltiazem | Nifedipine |
01 | 26 | M | 47 | 360 | 160 |
03 | 23 | F | 100 | 360 | 80 |
04 | 21 | F | 96 | 360 | 40 |
05 | 24 | F | 89 | 360 | 120 |
06 | 20 | F | 84 | 360 | 80 |
07 | 38 | M | 52 | 240 | 80 |
08 | 24 | F | 60 | 360 | 80 |
09 | 25 | M | 68 | 360 | 80 |
10 | 23 | M | 75 | 480 | 120 |
11 | 23 | M | 71 | 360 | 80 |
12 | 22 | M | 47 | 480 | 80 |
13 | 19 | F | 94 | 480 | 120 |
14 | 32 | M | 60 | 360 | 80 |
15 | 35 | M | 98 | 480 | 120 |
16 | 24 | M | 78 | 480 | 120 |
17 | 20 | F | 60 | 480 | 120 |
18 | 22 | F | 66 | 480 | 40 |
20 | 26 | M | 71 | 240 | 40 |
21 | 18 | M | 63 | 360 | 80 |
23 | 22 | F | 91 | 360 | 40 |
24 | 24 | M | 82 | 360 | 40 |
25 | 23 | M | 91 | 480 | 80 |
27 | 24 | F | 68 | 360 | 160 |
30 | 24 | F | 100 | 360 | 40 |
Mean | 24 | 13M/11F | 75 | 390 | 87 |
s.e. mean | 1 | 3 | 15 | 7 |
Three of the subjects were excluded from final data analysis because of packaging errors in the blinded treatments.